Evidence map›Paper›PMID 33226648›Full record

ArticleCA: a cancer journal for clinicians2021

Time to add screening for financial hardship as a quality measure?

Cathy J Bradley, K Robin Yabroff, S Yousuf Zafar, Ya-Chen Tina Shih

Abstract read
In one paragraph

Article in CA: a cancer journal for clinicians, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Financial Burden of Hepatocellular Carcinoma Screening in Patients With Cirrhosis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024
    Trial
  3. Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  4. Article
  5. Cancer and Health Inequalities.British journal of cancer · 2026
    Review
  6. Article
  7. Financial toxicity among breast cancer survivors receiving care during the pandemic.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Financial burden of high-cost immunotherapy among cancer survivors in Medicare.Journal of cancer survivorship : research and practice · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cathy J BradleyUniversity of Colorado Comprehensive Cancer Center and Colorado School of Public Health, Aurora, Colorado.ORCID 0000-0001-9429-6567
K Robin YabroffSurveillance and Health Services Research Program, American Cancer Society, Atlanta, Georgia.
S Yousuf ZafarDuke Cancer Institute, Duke-Margolis Center for Health Policy, Durham, North Carolina.
Ya-Chen Tina ShihSection of Cancer Economics and Policy, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Funding

Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic ImplicationsR01CA225647 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHIH, YA-CHEN TINA · 2019 to 2023
$1.8M
Technology Diffusion in Cancer: Geographic Variations, Facilitators, Outcomes, and CostsR01CA207216 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHIH, YA-CHEN TINA · 2016 to 2020
$1.6M
INHERITANCE &MARKERS OF COLORECTAL CANCER &POLYPSR01CA044688 · NCI · CEDARS-SINAI MEDICAL CENTER · PI PETERSON, GLORIA M · 1987 to 1989
–
Health Care Services Corporation/BCBSTXNCI NIH HHS P30CA44688NCI NIH HHS R01 CA207216NCI NIH HHS R01 CA225647
6 · The paper itself

Abstract

Cancer treatment is associated with financial hardship for many patients and families. Screening for financial hardship and referrals to appropriate resources for mitigation are not currently part of most clinical practices. In fact, discussions regarding the cost of treatment occur infrequently in clinical practice. As the cost of cancer treatment continues to rise, the need to mitigate adverse consequences of financial hardship grows more urgent. The introduction of quality measurement and reporting has been successful in establishing standards of care, reducing disparities in receipt of care, and improving other aspects of cancer care outcomes within and across providers. The authors propose the development and adoption of financial hardship screening and management as an additional quality metric for oncology practices. They suggest relevant stakeholders, conveners, and approaches for developing, testing, and implementing a screening and management tool and advocate for endorsement by organizations such as the National Quality Forum and professional societies for oncology care clinicians. The confluence of increasingly high-cost care and widening disparities in ability to pay because of underinsurance and lack of health insurance coverage makes a strong argument to take steps to mitigate the financial consequences of cancer.

Indexed as

Cost of IllnessQuality Indicators, Health CareFinancial StressHealthcare DisparitiesHumansMedically UninsuredMedical OncologyNeoplasmscancerdisparitiesfinancial hardshipquality measurementscreening

Identifiers

PMID33226648
PMCPMC9116031

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.